Blog

T cells

New FDA guidance: cell therapies and patient identifiers

When the US Food and Drug Administration (FDA) recently made two draft guidance documents for the cell and gene therapies available for comment, the Vineti team was quick to scan for one three-letter phrase that is core to our mission – COI.

Read More
January 30, 2020

Data management for advanced therapies, Part 4: working with multiple stakeholders

Note: this post is the fourth in an eight-part series on data management strategies for personalized therapies, such as cell...

January 15, 2020

Vineti Announces New Board of Directors Member

SAN FRANCISCO, January 15, 2020 — Vineti, Inc., the provider of the leading digital platform of record for personalized therapeutics,...

January 8, 2020

Data management for advanced therapies, Part 3: working with living cells

Note: this post is the third in an eight-part series on data management strategies for personalized therapies, such as cell...

December 30, 2019

Advanced therapy supply chains: lessons from 100 meetings

You can learn a lot in 100 meetings. In 2019, I conducted more than 100 discussions on advanced therapy supply...

December 17, 2019

WoVen, a podcast from Canaan featuring Amy DuRoss

One of Vineti’s board members, Nina Kjellson, General Partner, at Canaan started a podcast called WoVen, about women who venture. We’re excited to...

December 4, 2019

Data management for advanced therapies, Part 2: unique data features

Note: this post is the second of an eight-part series on data management strategies for personalized therapies, such as cell...

December 4, 2019

Data management for advanced therapies, Part 1: the need for new strategies

Note: this post is the first of an eight-part series on data management strategies for personalized therapies, such as cell...

November 26, 2019

Design for Healthcare IRL at Vineti, a Meetup

More and more of today’s healthcare happens online and digital is just one part of the picture. Much of the...

November 15, 2019

Eight million pages, the Space Shuttle, and other highlights from BMWS 2019

If you’re producing cell therapy products for 10,000 patients a year, how many release tests will be required? If making...

November 6, 2019

More kaizen for cell and gene therapy

Today, Vineti is excited to announce a new partnership with a global contract manufacturing company serving cell and gene therapies — and...

October 30, 2019

Chain of Identity and Chain of Custody in personalized therapies — core differences from traditional pharma

In pharmaceutical manufacturing, Chain of Identity and Chain of Custody may not be new — but in advanced therapy manufacturing,...

October 23, 2019

Q&A with Dr. Mike Pellini: the need for advanced software to scale cell and gene therapies

Mike Pellini, M.D., is a member of Vineti’s Board of Directors, a Managing Partner at Section 32, and the former...